RT Journal Article
SR Electronic
T1 Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.23.20077123
DO 10.1101/2020.04.23.20077123
A1 Danielle Klinger
A1 Ido Blass
A1 Nadav Rappoport
A1 Michal Linial
YR 2020
UL http://medrxiv.org/content/early/2020/05/12/2020.04.23.20077123.abstract
AB COVID-19 has spread to 210 countries within 3 months. We tested the hypothesis that the vaccination with BCG correlates with a better outcome for COVID-19 patients. Our analysis covers 55 countries, complying with predetermined thresholds on population size and deaths per million (DPM). We found a strong negative correlation between the years of BCG administration and a lower DPM along with the pandemic progression in time. The results from multivariable regression tests with 22 economical, demographic, and health-related quantitative properties for each country substantiate the dominant contribution of BCG administration years to the COVID-19 outcomes. Analyzing countries according to an age-group partition reveals that the strongest correlation is attributed to the coverage in BCG vaccination of the young population and mostly to recent years immunization. We propose that BCG immunization coverage, especially among the most recently vaccinated contributes to attenuation of the spread and severity of the COVID-19 pandemic.One Sentence Summary BCG vaccination regimes and COVID-19 outcomesCompeting Interest StatementThe authors have declared no competing interest.Funding StatementInterdisciplinary Data Science Research (CIRD), the Hebrew University of JerusalemAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAn online tool for displaying the analytical results is available at: https://covi.shinyapps.io/COVID19/. Code and data is available at: https://github.com/nadavrap/COVID19. https://github.com/nadavrap/COVID19 https://covi.shinyapps.io/COVID19/.